 Michael Kriss
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 9 | 2023 | 843 | 2.480 |
Why?
| | Non-alcoholic Fatty Liver Disease | 4 | 2020 | 277 | 0.990 |
Why?
| | Gastroenterologists | 2 | 2021 | 17 | 0.970 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2023 | 107 | 0.960 |
Why?
| | Gastric Antral Vascular Ectasia | 1 | 2023 | 2 | 0.920 |
Why?
| | Liver | 8 | 2021 | 1803 | 0.820 |
Why?
| | Esophageal and Gastric Varices | 1 | 2021 | 40 | 0.780 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2021 | 39 | 0.770 |
Why?
| | Osteopontin | 1 | 2020 | 38 | 0.750 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 38 | 0.750 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2021 | 202 | 0.690 |
Why?
| | Job Satisfaction | 1 | 2021 | 172 | 0.680 |
Why?
| | Burnout, Professional | 2 | 2021 | 322 | 0.670 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 648 | 0.480 |
Why?
| | Acute-On-Chronic Liver Failure | 2 | 2023 | 6 | 0.440 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1197 | 0.440 |
Why?
| | Gastrointestinal Microbiome | 1 | 2019 | 538 | 0.420 |
Why?
| | Liver Cirrhosis | 3 | 2023 | 243 | 0.290 |
Why?
| | Hepatitis C, Chronic | 2 | 2019 | 151 | 0.280 |
Why?
| | Living Donors | 3 | 2023 | 318 | 0.260 |
Why?
| | Prevalence | 2 | 2021 | 2321 | 0.250 |
Why?
| | Hepacivirus | 2 | 2017 | 230 | 0.250 |
Why?
| | Electrocoagulation | 1 | 2023 | 36 | 0.220 |
Why?
| | Lymphatic Vessels | 2 | 2020 | 54 | 0.220 |
Why?
| | Lipoproteins, LDL | 2 | 2020 | 138 | 0.220 |
Why?
| | Severity of Illness Index | 2 | 2021 | 2659 | 0.220 |
Why?
| | Endothelial Cells | 2 | 2019 | 717 | 0.200 |
Why?
| | Waiting Lists | 1 | 2023 | 228 | 0.200 |
Why?
| | Humans | 17 | 2023 | 118257 | 0.200 |
Why?
| | Tissue Donors | 1 | 2023 | 334 | 0.200 |
Why?
| | Training Support | 1 | 2021 | 24 | 0.190 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 54 | 0.190 |
Why?
| | Fatty Liver | 1 | 2023 | 247 | 0.180 |
Why?
| | Liver Diseases | 1 | 2023 | 282 | 0.180 |
Why?
| | Tissue and Organ Procurement | 1 | 2023 | 247 | 0.170 |
Why?
| | Liver Regeneration | 1 | 2019 | 34 | 0.170 |
Why?
| | Medicine | 1 | 2021 | 106 | 0.170 |
Why?
| | Prognosis | 3 | 2023 | 3424 | 0.170 |
Why?
| | Physician's Role | 1 | 2021 | 200 | 0.170 |
Why?
| | ROC Curve | 1 | 2020 | 470 | 0.170 |
Why?
| | Career Choice | 1 | 2021 | 192 | 0.170 |
Why?
| | Acute Disease | 1 | 2021 | 933 | 0.160 |
Why?
| | Coronary Angiography | 1 | 2020 | 311 | 0.160 |
Why?
| | Respiratory Insufficiency | 1 | 2022 | 289 | 0.160 |
Why?
| | United States | 4 | 2023 | 12491 | 0.160 |
Why?
| | Academic Medical Centers | 1 | 2021 | 422 | 0.160 |
Why?
| | Transplantation, Homologous | 1 | 2019 | 412 | 0.150 |
Why?
| | Dysbiosis | 1 | 2019 | 148 | 0.150 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 1124 | 0.150 |
Why?
| | Logistic Models | 1 | 2021 | 1896 | 0.140 |
Why?
| | Adult | 4 | 2021 | 31325 | 0.140 |
Why?
| | Cholestasis | 1 | 2019 | 228 | 0.140 |
Why?
| | Hospitals | 1 | 2021 | 600 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1857 | 0.130 |
Why?
| | Middle Aged | 5 | 2023 | 27511 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2019 | 526 | 0.130 |
Why?
| | Autocrine Communication | 1 | 2014 | 42 | 0.130 |
Why?
| | Transcriptome | 1 | 2020 | 752 | 0.130 |
Why?
| | Immunity, Innate | 2 | 2017 | 744 | 0.120 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1322 | 0.120 |
Why?
| | Male | 7 | 2021 | 57476 | 0.120 |
Why?
| | Kidney Transplantation | 1 | 2020 | 576 | 0.120 |
Why?
| | Interferons | 1 | 2014 | 151 | 0.120 |
Why?
| | Exosomes | 1 | 2014 | 92 | 0.120 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2435 | 0.120 |
Why?
| | Disease Progression | 1 | 2020 | 2477 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2020 | 3156 | 0.110 |
Why?
| | Aged, 80 and over | 2 | 2021 | 6541 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2023 | 12929 | 0.110 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4684 | 0.110 |
Why?
| | Hospitalization | 1 | 2021 | 1778 | 0.110 |
Why?
| | Virus Replication | 1 | 2014 | 398 | 0.110 |
Why?
| | Female | 5 | 2021 | 61262 | 0.100 |
Why?
| | Cell Differentiation | 1 | 2019 | 1746 | 0.100 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 4522 | 0.100 |
Why?
| | Hypercholesterolemia | 1 | 2011 | 93 | 0.090 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2011 | 125 | 0.090 |
Why?
| | Risk Factors | 2 | 2022 | 8958 | 0.090 |
Why?
| | Cohort Studies | 1 | 2020 | 5078 | 0.090 |
Why?
| | Single-Cell Analysis | 2 | 2020 | 186 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2019 | 2230 | 0.080 |
Why?
| | Aged | 3 | 2021 | 19594 | 0.080 |
Why?
| | Treatment Outcome | 1 | 2021 | 9319 | 0.070 |
Why?
| | Inflammation | 1 | 2017 | 2545 | 0.070 |
Why?
| | Young Adult | 1 | 2021 | 10731 | 0.070 |
Why?
| | Hepatocytes | 2 | 2017 | 204 | 0.060 |
Why?
| | Adolescent | 1 | 2021 | 18364 | 0.060 |
Why?
| | North America | 1 | 2022 | 265 | 0.050 |
Why?
| | Mice | 4 | 2020 | 15446 | 0.050 |
Why?
| | Intercellular Junctions | 1 | 2020 | 34 | 0.050 |
Why?
| | Proteostasis | 1 | 2020 | 20 | 0.050 |
Why?
| | Permeability | 1 | 2020 | 154 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2020 | 3676 | 0.040 |
Why?
| | Nephrectomy | 1 | 2020 | 162 | 0.040 |
Why?
| | Graft Survival | 1 | 2021 | 497 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2020 | 247 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 1 | 2020 | 287 | 0.040 |
Why?
| | Obesity | 1 | 2011 | 2715 | 0.040 |
Why?
| | Isoquinolines | 1 | 2017 | 41 | 0.040 |
Why?
| | Benzazepines | 1 | 2017 | 38 | 0.040 |
Why?
| | Carbamates | 1 | 2017 | 37 | 0.040 |
Why?
| | Pyrrolidines | 1 | 2017 | 57 | 0.040 |
Why?
| | Valine | 1 | 2017 | 77 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2020 | 469 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 410 | 0.040 |
Why?
| | Imidazoles | 1 | 2017 | 227 | 0.040 |
Why?
| | Animals | 4 | 2020 | 33152 | 0.030 |
Why?
| | Indoles | 1 | 2017 | 311 | 0.030 |
Why?
| | Clathrin | 1 | 2014 | 27 | 0.030 |
Why?
| | Sulfonamides | 1 | 2017 | 444 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 3043 | 0.030 |
Why?
| | Chronic Disease | 1 | 2019 | 1630 | 0.030 |
Why?
| | Interleukins | 1 | 2014 | 242 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2017 | 653 | 0.030 |
Why?
| | Cholesterol, Dietary | 1 | 2011 | 16 | 0.030 |
Why?
| | Prealbumin | 1 | 2011 | 23 | 0.030 |
Why?
| | Calorimetry, Indirect | 1 | 2011 | 72 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1072 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 2011 | 104 | 0.020 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2011 | 178 | 0.020 |
Why?
| | Bile Acids and Salts | 1 | 2011 | 179 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 482 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 4887 | 0.020 |
Why?
| | Fatty Acids | 1 | 2011 | 403 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 862 | 0.020 |
Why?
| | Weight Gain | 1 | 2011 | 485 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4044 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2011 | 529 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2011 | 2012 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2011 | 762 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1870 | 0.020 |
Why?
| | Phenotype | 1 | 2011 | 2937 | 0.010 |
Why?
| | Child | 1 | 2021 | 19033 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 6368 | 0.010 |
Why?
|
|
Kriss's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|